Vaccine Prevention of Rabies Adopts 4-shot Immunization Method

Summary

A phase III clinical trial to evaluate the immunogenicity and safety of freeze-dried human rabies vaccine (Vero cell) developed by Changchun Zhuoyi Biological Co., Ltd. inoculated in a 4-dose procedure (2-1-1)

Timeline

Start

2020-07-22

Primary completion

2021-10-31

Completion

2023-04-20

Outcome

Met primary endpoint

paper The vaccine in the four-dose test group is equivalent in immunogenic effect to the four-dose control group vaccine and superior to the five-dose control group vaccine; PMID 38937182 ↗

Publications

• Jin F, Zhu L, Wang Y, Qin G, Tian Y, Xie Y, Jin H, Zhang Y, Wang L, Li J, Wu Z, Sheng Y, Shi L, Yang G, Zhao Z, Chen L, Chen P, Jiang Z, Yu J, Gao Z, Li Q, Wu X, Miao L. Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic. Vaccine. 2024 Oct 3;42(23):126059. doi: 10.1016/j.vaccine.2024.06.026. Epub 2024 Jun 27.

Drugs

Indications